SCHEMBL10125933

SCHEMBL10125933

Cc1cc(C)cc(-c2ccc(-c3cc(C)cc(C)c3)c3nc(-c4ccc(-c5ccc(-c6nc7ccccc7o6)cc5)cc4)c(-c4ccccc4)nc23)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 11/20 0.51
RAB9A P51151 9/20 0.51
SMN1; SMN2 Q16637 8/20 0.51
KDM4E B2RXH2 8/20 0.51
HPGD P15428 7/20 0.51
CASP3 P42574 2/20 0.51
SENP8 Q96LD8 2/20 0.51
SENP7 Q9BQF6 2/20 0.51
SENP6 Q9GZR1 2/20 0.51
POLB P06746 1/20 0.51
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
ATM Q13315 1/20 0.50
MAPT P10636 5/20 0.45
TP53 P04637 4/20 0.45
ALDH1A1 P00352 7/20 0.45
USP2 O75604 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
HCRTR1 O43613 2/20 0.44
NFKB1 P19838 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10126059 0.98 NPC1 (0.52) NPC1RAB9ASMN1; SMN2KDM4EHPGD
SCHEMBL10315198 0.91 NPC1 (0.45) NPC1RAB9ASMN1; SMN2KDM4EHPGD
SCHEMBL10125943 0.90 NPC1 (0.53) NPC1RAB9ASMN1; SMN2KDM4EHPGD
SCHEMBL10315421 0.90 NPC1 (0.45) NPC1RAB9ASMN1; SMN2KDM4EHPGD
SCHEMBL10125938 0.89 NPC1 (0.52) NPC1RAB9ASMN1; SMN2KDM4EHPGD
SCHEMBL10125986 0.89 NPC1 (0.55) NPC1RAB9ASMN1; SMN2KDM4EHPGD
SCHEMBL10125978 0.89 NPC1 (0.55) NPC1RAB9ASMN1; SMN2KDM4EHPGD
SCHEMBL10125801 0.89 NPC1 (0.55) NPC1RAB9ASMN1; SMN2KDM4EHPGD
SCHEMBL10125792 0.89 NPC1 (0.55) NPC1RAB9ASMN1; SMN2KDM4EHPGD
SCHEMBL10125940 0.88 NPC1 (0.49) NPC1RAB9ASMN1; SMN2KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119259-B2 Quinoxaline derivative, and light-emitting element and electronic device using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-02-21 US disclosed
US-8119259-B2 Quinoxaline derivative, and light-emitting element and electronic device using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-02-21 US disclosed
US-20090140642-A1 Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-06-04 US disclosed
US-20090140642-A1 Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090140642-A1 Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same NDUFA11, NDUFA9, NDUFA12 NPC1 4763/4885RAB9A 1141/4885SMN1; SMN2 3688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.